StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) stock

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.37−0.14 (-9.27%)

Close on Nov 18, 2026Market cap $2.52MP/E –Yield –

NeuroSense Therapeutics cash

Cash and short-term investments held at the end of each period.

NeuroSense Therapeutics's cash was $231.00K at Jun 30, 2026. For fiscal 2025 it was $166.00K, down 95.1% from the year before. The highest annual figure on record is $11.06M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$166.00K-95.1%
FY2024Dec 31, 2024$3.38M+28.0%
FY2023Dec 31, 2023$2.64M-25.5%
FY2022Dec 31, 2022$3.54M-68.0%
FY2021Dec 31, 2021$11.06M+1482.7%
FY2020Dec 31, 2020$699.00K-21.9%
FY2019Dec 31, 2019$895.00K+940.7%
FY2018Dec 31, 2018$86.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$231.00K-80.9%
Q4 FY2025Dec 31, 2025$166.00K-93.7%
Q2 FY2025Jun 30, 2025$666.00K-90.6%
Q4 FY2024Dec 31, 2024$3.38M-4.7%
Q2 FY2024Jun 30, 2024$1.21M-72.2%
Q4 FY2023Dec 31, 2023$2.64M-76.1%
Q2 FY2023Jun 30, 2023$7.09M+613.2%
Q4 FY2022Dec 31, 2022$3.54M+406.9%
Q2 FY2022Jun 30, 2022$4.35M+385.9%
Q4 FY2021Dec 31, 2021$11.06M+12764.0%
Q2 FY2021Jun 30, 2021$994.00K–
Q4 FY2020Dec 31, 2020$699.00K–
Q4 FY2019Dec 31, 2019$895.00K–
Q4 FY2018Dec 31, 2018$86.00K–

More NeuroSense Therapeutics figures

See a number that looks wrong?